AGC via its subsidiary AGC Biologics has signed an agreement with Novartis Gene Therapies to purchase a cell and gene therapy manufacturing facility located in Colorado, USA.

The addition of this facility follows last year’s acquisition of the Italian company MolMed which is currently undergoing expansion.

Once approved, the facility will be integrated into AGC Biologics' network, and services will be extended incorporating the former MolMed site, providing commercial GMP-compliant cell and gene therapy CDMO services, utilising the facility’s large floor space at over 60,000 square meters.

Furthermore, AGC Biologics Heidelberg Site has an established plasmid DNA production service, enabling it to offer end-to-end cell and gene services, which will also become part of the comapny's offering.

The sales target for the Group’s Life Science business is 180 billion yen (US $27 billion) or more for 2025.